openPR Logo

Press Releases from Companion Diagnostics Market (7 total)

Companion Diagnostics Market Size 2020-26, QIAGEN, Agilent, BioMerieux

The latest study on the Global Companion Diagnostics market report represents a deep appraisal of the international industry. The research report on the worldwide Companion Diagnostics market 2020-2026 sheds light on qualitative as well as quantitative insights, historical Companion Diagnostics industry status and authorized projection related to the Companion Diagnostics market size. Each and every segment exhibited in this report are discovered through verifiable research methods and techniques. It also

Companion Diagnostics Market to Witness Steady Growth at 32.3% CAGR During 2016 …

Researchmoz added Most up-to-date research on "Companion Diagnostics: Technologies and Markets" to its huge collection of research reports. Report Highlights The global market for companion diagnostics reached nearly $3.2 billion in 2015. This market is expected to increase from $4.3 billion in 2016 to nearly $17.6 billion in 2021 at a compound annual growth rate (CAGR) of 32.3% for 2016-2021. Report Includes An overview of the market for companion diagnostics, including existing products on

Companion Diagnostics Market - Analysis And Forecast (2016-2024): Market Shares …

Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying

CMI Releases New Report on the Companion Diagnostics Market,2017-2024.

The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic

COMPANION DIAGNOSTICS MARKET TO SURPASS US$ 5.0 BILLION BY 2024 : CMI

The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic

Companion Diagnostics Market to Surpass US$ 5.0 Billion by 2024

The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic

Companion Diagnostics Market - Global Industry Analysis 2024

Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying

Go To Page:   1 2 3 4 5 6 7 8 9 10